{
  "id": "5c6636c57c78d69471000011",
  "type": "summary",
  "question": "What is the mechanism of action of arimoclomol?",
  "ideal_answer": "Arimoclomol is a heat shock protein co-inducer that promotes nascent protein folding. It enhances the ability of differentiated neurons to survive heat shock.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27009270",
    "http://www.ncbi.nlm.nih.gov/pubmed/15034571",
    "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
    "http://www.ncbi.nlm.nih.gov/pubmed/19938902",
    "http://www.ncbi.nlm.nih.gov/pubmed/22591194",
    "http://www.ncbi.nlm.nih.gov/pubmed/29367439",
    "http://www.ncbi.nlm.nih.gov/pubmed/27605553",
    "http://www.ncbi.nlm.nih.gov/pubmed/27273088",
    "http://www.ncbi.nlm.nih.gov/pubmed/20582873",
    "http://www.ncbi.nlm.nih.gov/pubmed/21445803",
    "http://www.ncbi.nlm.nih.gov/pubmed/19183864",
    "http://www.ncbi.nlm.nih.gov/pubmed/30497978",
    "http://www.ncbi.nlm.nih.gov/pubmed/24853414",
    "http://www.ncbi.nlm.nih.gov/pubmed/18551622",
    "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
    "http://www.ncbi.nlm.nih.gov/pubmed/29090408",
    "http://www.ncbi.nlm.nih.gov/pubmed/29159344",
    "http://www.ncbi.nlm.nih.gov/pubmed/23393146"
  ],
  "snippets": [
    {
      "text": "Low dose co-application of celastrol and arimoclomol, which induces Hsps, enhanced the ability of differentiated neurons to survive heat shock.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To examine the safety and tolerability as well as the preliminary efficacy of arimoclomol, a heat shock protein co-inducer that promotes nascent protein folding, in patients with rapidly progressive SOD1 amyotrophic lateral sclerosis (ALS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29367439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30497978",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The investigational drug arimoclomol, which is in phase II/III clinical trials, is a well-characterized HSP amplifier and has been extensively clinically tested. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30497978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Regioselective and enantiospecific synthesis of the HSP co-inducer arimoclomol from chiral glycidyl derivatives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159344",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Oral administration of arimoclomol, a small-molecule coinducer of HSPs that is currently in clinical trials for Niemann-Pick disease type C (NPC), recapitulated the effects of recombinant human HSP70, suggesting that heat shock protein-based therapies merit clinical evaluation for treating LSDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605553",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using rat myoblast cultures, we found that up-regulation of the heat shock response with arimoclomol reduced key pathological markers of sIBM in vitro. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009270",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have previously shown that treatment with a co-inducer of the heat shock response called arimoclomol is effective in the SOD(G93A) mouse model of ALS, delaying disease progression and extending the lifespan of SOD(G93A) mice (Kieran et al.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arimoclomol is a hydroxylamine derivative, a group of compounds which have unique properties as co-inducers of heat shock protein expression, but only under conditions of cellular stress.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18551622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arimoclomol is a co-activator that prolongs the binding of activated HSF1 to heat shock elements (HSEs) in the promoter regions of inducible Hsp genes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The investigational drug arimoclomol, which is in phase II/III clinical trials, is a well-characterized HSP amplifier and has been extensively clinically tested.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30497978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19938902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE To examine the safety and tolerability as well as the preliminary efficacy of arimoclomol, a heat shock protein co-inducer that promotes nascent protein folding, in patients with rapidly progressive SOD1 amyotrophic lateral sclerosis (ALS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29367439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have previously shown that treatment with arimoclomol, a co-inducer of the heat shock stress response, delays disease progression in the mutant superoxide dismutase 1 mouse model of amyotrophic lateral sclerosis, a fatal motor neuron disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23393146",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18551622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review we summarize the evidence for the neuroprotective effects of enhanced heat shock protein expression by Arimoclomol and other inducers of the Heat Shock Response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23978556",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}